Pediatric Praziquantel Consortium

Developing and providing a pediatric formulation of the drug praziquantel, to treat schistosomiasis in preschool-aged children

The Pediatric Praziquantel Consortium targets preschool-aged children with schistosomiasis, a parasitic disease that affects more than 240 million people worldwide. The consortium was established in July 2012, and uses an innovative R&D operating model that builds new partnerships as needed and shares development risks.

icon_Hands 8

partners since 2016

icon_Clock 6 years

duration of the program

About the Pediatric Praziquantel Consortium

Praziquantel (PZQ), the gold standard treatment for schistosomiasis, is currently available in large oral tablets that are suitable only for adults and school-aged children. Due to the size of the tablet, its bitter taste, and a lack of clinical data, an appropriate treatment for very young children does not exist. The consortium addresses this issue, and has developed a new orally disintegrating PZQ formulation that is currently in clinical development. The consortium is supported by grants from the Bill and Melinda Gates Foundation in 2013 and the Global Health Initiative Technology Fund in 2014 and 2015. Visit the Pediatric Praziquantel Consortium website for more information about the program.

Bridging industry interests and societal needs

TI Pharma – now part of Lygature – helped to set up the consortium and fulfils an independent ‘broker’ role, a key ingredient of successful public-private development partnerships. Reflecting the consortium’s position at the crossroad between industry and society, the contributions being made by Lygature from January 2016 include: 

  • Coordination and governance. As consortium coordinator, Lygature provides necessary governance in terms of monitoring progress, finance, IP management, and collaborations. In addition, it successfully takes the lead in fundraising to support the clinical trial program (current total value: EUR 5m).  
  • Communication and dissemination . Lygature pro-actively coordinates the engagement with key stakeholders to share the consortium’s ambition to make a meaningful contribution to tropical medicine and health innovation in endemic countries. Responsibilities include (but are not limited to): presenting at (inter)national conferences; writing of (scientific) articles and news items; and development of the consortium’s communication strategy, website, and visual identity. 

The Pediatric Praziquantel Consortium is an example of the Lygature mission to bring together public and private partners, and so to make a meaningful contribution to tropical medicine. The project relies heavily on Lygature’s expertise in both management and science. In addition, Lygature has helped to ensure that each partner’s needs, interests, and objectives are met.

Lygature together with

Project updates

  • Banner for world NTD day

    The Pediatric Praziquantel Consortium supports first ever World Neglected Tropical Diseases Day

    Thursday, 30 January 2020, marked the inaugural World Neglected Tropical Diseases (NTD) Day, an initiative created to draw attention to priority issues surrounding NTDs and the efforts being made to combat them.

    As a project focused on making a meaningful contribution to tropical medicine, the Pediatric Praziquantel Consortium is proud to be amongst the more than 230 partners from around the world to have signed up to support World NTD Day.

    Read more.

  • Two wooden figures

    We have launched the Phase III clinical trial

    This trial seeks to evaluate the safety and efficacy of pediatric praziquantel in Schistosoma-infected children of 3 months to 6 years of age in Côte d’Ivoire and Kenya. The trial is a crucial part of the development program for the new child-friendly praziquantel orally dispersible tablet formulation. The trial designed by the Consortium’s clinical sub team, will be managed by the Medicine Department at the Swiss Tropical and Public Health Institute (Swiss TPH) and supervised by the Pediatric Praziquantel Consortium project team, led by Merck.

    Read more.

  • A new formulation to fight Schistosomiasis

    The GHIT Fund, one of the funders for the Pediatric Praziquantel Consortium, created a 4 minute video explaining the Consortium’s work and its current challenges. 

    Watch the video here